Advanced Filters
noise

multiple-myeloma Clinical Trials

A listing of multiple-myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 551 clinical trials
B Brent LaStofka

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.

19 years of age All Phase 2
S Supratik Basu

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel …

18 years of age All Phase N/A
H He Huang, Doctor

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.

18 - 75 years of age All Phase 1/2

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days …

18 years of age All Phase N/A

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an open-label, multicenter, non-comparative, 2-cohort, 2-stage with interruption of enrollment for an efficacy …

65 years of age All Phase 2
S Site Contact

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.

18 years of age All Phase 1

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

18 years of age All Phase 1
A Ashlee Young, Trial Activation Coordinator

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety …

18 years of age All Phase 2
V Vitaly Dubov, MD

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence …

18 - 80 years of age All Phase 1/2
J Juan Du, MD

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.

18 years of age All Phase 0

Simplify language using AI